Aclidinium bromide provides long-acting bronchodilation in patients with COPD.

@article{Chanez2010AclidiniumBP,
  title={Aclidinium bromide provides long-acting bronchodilation in patients with COPD.},
  author={Pascal Chanez and Peter Burge and Ronald Dahl and Jacques P H M Creemers and Alexandr G. Chuchalin and Rosa Lamarca and Esther Garcia Gil},
  journal={Pulmonary pharmacology & therapeutics},
  year={2010},
  volume={23 1},
  pages={15-21}
}
Aclidinium bromide is a novel, long-acting, muscarinic antagonist in phase III development for the maintenance treatment of COPD. This phase IIb study investigated the efficacy and safety of aclidinium for the treatment of moderate to severe COPD to establish the optimal dose for phase III studies. A total of 464 patients with moderate to severe stable COPD were randomised to double-blind, once-daily treatment with aclidinium (25, 50, 100, 200, or 400microg), placebo, or open-label tiotropium… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients.

Respiratory physiology & neurobiology • 2013
View 4 Excerpts
Highly Influenced

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease

International journal of chronic obstructive pulmonary disease • 2015

Positioning new pharmacotherapies for COPD

International journal of chronic obstructive pulmonary disease • 2015
View 1 Excerpt

Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists • 2014

Clinical use of aclidinium in patients with COPD

International journal of chronic obstructive pulmonary disease • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…